These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1175 related articles for article (PubMed ID: 27893331)

  • 21. Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial.
    Kirkham AA; Pituskin E; Thompson RB; Mackey JR; Koshman SL; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Tsui AK; Ezekowitz JA; Oudit GY; Paterson DI
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):130-139. PubMed ID: 33605416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
    Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
    Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
    Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.
    Barron CC; Alhussein MM; Kaur U; Cosman TL; Tyagi NK; Brown M; Mukherjee SD; Ellis PM; Dhesy-Thind S; Leong DP
    Curr Oncol; 2019 Aug; 26(4):240-246. PubMed ID: 31548803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
    van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
    Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
    Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
    Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.
    Lee S; Alsamarrai A; Xiao A; Wang TKM
    Intern Med J; 2024 Aug; 54(8):1254-1263. PubMed ID: 38874281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
    Gulati G; Heck SL; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; von Knobelsdorff-Brenkenhoff F; Bratland Å; Storås TH; Hagve TA; Røsjø H; Steine K; Geisler J; Omland T
    Eur Heart J; 2016 Jun; 37(21):1671-80. PubMed ID: 26903532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
    Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
    Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
    Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
    Bouwer NI; Steenbruggen TG; Rier HN; Kitzen JJEM; Smorenburg CH; van Bekkum ML; de Jong PC; Drooger JC; Holterhues C; Kofflard MJM; Boersma E; Sonke GS; Levin MD; Jager A
    Int J Cancer; 2022 Aug; 151(4):616-622. PubMed ID: 35403708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
    Livi L; Barletta G; Martella F; Saieva C; Desideri I; Bacci C; Del Bene MR; Airoldi M; Amoroso D; Coltelli L; Scotti V; Becherini C; Visani L; Salvestrini V; Mariotti M; Pedani F; Bernini M; Sanchez L; Orzalesi L; Nori J; Bianchi S; Olivotto I; Meattini I
    JAMA Oncol; 2021 Oct; 7(10):1544-1549. PubMed ID: 34436523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.